Free Trial
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

iTeos Therapeutics logo
$10.13 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$10.12 -0.01 (-0.05%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Key Stats

Today's Range
$10.11
$10.14
50-Day Range
$9.95
$10.35
52-Week Range
$4.80
$18.01
Volume
1.24 million shs
Average Volume
1.04 million shs
Market Capitalization
$447.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Hold

Company Overview

iTeos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

ITOS MarketRank™: 

iTeos Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 485th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iTeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    iTeos Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about iTeos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iTeos Therapeutics is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iTeos Therapeutics is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    iTeos Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about iTeos Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.83% of the float of iTeos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    iTeos Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iTeos Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving.
  • Dividend Yield

    iTeos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    iTeos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.83% of the float of iTeos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    iTeos Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iTeos Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving.
  • News Sentiment

    iTeos Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for iTeos Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for ITOS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,805,412.00 in company stock.

  • Percentage Held by Insiders

    14.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about iTeos Therapeutics' insider trading history.
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ITOS Stock News Headlines

A Major Economic Change Is Happening Now
Louis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and earning a reputation for fact-based analysis, not sensationalism. That’s why his latest economic warning is turning so many heads. In his new report, Louis reveals how recent policies are accelerating a massive economic shift. While headlines point to strong numbers, everyday Americans feel the squeeze as prices climb and industries are reshaped. According to Louis, this transformation could determine who falls behind — and who builds lasting wealth.tc pixel
See More Headlines

ITOS Stock Analysis - Frequently Asked Questions

iTeos Therapeutics' stock was trading at $7.68 at the beginning of 2025. Since then, ITOS stock has increased by 31.9% and is now trading at $10.13.

iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by $0.39.

iTeos Therapeutics (ITOS) raised $151 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

iTeos Therapeutics' top institutional shareholders include EcoR1 Capital LLC (24.18%), Geode Capital Management LLC (1.84%), Orbimed Advisors LLC (1.58%) and Marshall Wace LLP (1.38%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2018 LP Mpm, Boxer Capital, Llc, Michel Detheux, Matthew Gall and David Hallal.
View institutional ownership trends
.

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/06/2025
Today
8/26/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITOS
CIK
1808865
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$46.00
Low Price Target
$8.00
Potential Upside/Downside
+53.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$134.41 million
Net Margins
N/A
Pretax Margin
-336.72%
Return on Equity
-33.26%
Return on Assets
-28.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.53
Quick Ratio
7.53

Sales & Book Value

Annual Sales
$35 million
Price / Sales
12.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.16 per share
Price / Book
0.63

Miscellaneous

Outstanding Shares
44,210,000
Free Float
37,928,000
Market Cap
$447.85 million
Optionable
Optionable
Beta
1.49

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ITOS) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners